1
Return

Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians

delete2026-05-20
delete0
PRE
AI
K
Kristian Beichmann
P
Polina Catzeflis
H
Helena Aicher
F
Federico Seragnoli
A
Abigail E. Calder
A
Adam Amrani
G
Gregor Hasler
DOI:10.1177/20451253261448745delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
<jats:sec> <jats:title>Background:</jats:title> <jats:p> The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy- <jats:italic toggle="yes">N</jats:italic> -methamphetamine (MDMA). </jats:p> </jats:sec> <jats:sec> <jats:title>Objectives:</jats:title> <jats:p>The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH).</jats:p> </jats:sec> <jats:sec> <jats:title>Design:</jats:title> <jats:p>Swiss PAT practices were examined using an anonymous survey of physicians providing PAT. Questions included physicians’ backgrounds, training, therapeutic orientation, treatment protocols, patient characteristics, and perceived benefits.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Participants were recruited from PAT professional associations and the research team network. Forty-one physicians providing PAT under FOPH exemptions contributed to the survey.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Respondents used PAT primarily for depression, anxiety, post-traumatic stress disorder (PTSD), and chronic pain. Most physicians practiced in private practices, private outpatient clinics or shared practices (82%), with a minority in hospitals (18%). The most reported labels when providing PAT were body-oriented (61%), psychodynamic (59%), and eclectic (54%) approaches. Respondents provided PAT using psilocybin (85%), MDMA (71%), and LSD (65.9%). Choice of first substance was linked to diagnosis, with physicians preferring psilocybin for depression (54%) and substance use disorder (46%) and MDMA for PTSD (86%) and anxiety disorders (54%). A total of 90% reported always playing music during psychedelic sessions. Loss of orientation in time and space, feeling too cold, anxiety, and nausea where the most frequent adverse effects of PAT. 95% had emergency medication available, on average used during 2.4% of sessions. Challenges included legal constraints, high patient expectations, and financial barriers. Group therapy was common, with 9% reporting providing only group sessions, 42% providing both individual and group settings, and 47% providing only individual sessions. Only 9% reported never using co-sitters.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>This study offers valuable insights into the methods and experiences of physicians providing PAT in a legal clinical context, giving insight into the considerable variety of clinical methods. Cultural and regulatory differences may limit generalizability.</jats:p> </jats:sec>

Journal

T
Therapeutic Advances in Psychopharmacology
IF:
4
Papers:
436
Citations:
1.5K

Organization

U
university of fribourg
Scholars:
682
Papers: 320
Citations: 0
U
university of basel
Scholars:
2.7K
Papers: 1.1K
Citations: 0
G
Geneva University Hospitals
Scholars:
585
Papers: 234
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers